1) The document proposes using value of information (VOI) analysis to calculate the value of transferability (applying results from a multinational trial to a specific country) in terms of expected value of sample information (EVSI).
2) It applies this method to results from the Scandinavian Simvastatin Survival Study, defining the posterior distribution of country results given the multinational trial results.
3) The value of transferability is measured as the difference between the prior and posterior expected value of perfect information (EVPI) for each country, indicating whether applying the multinational results reduces uncertainty.
This powerpoint presentation gives a brief explanation about the biostatic data .this is quite helpful to individuals to understand the basic research methodology terminologys
This powerpoint presentation gives a brief explanation about the biostatic data .this is quite helpful to individuals to understand the basic research methodology terminologys
Meta-analysis in Epidemiology is:
Useful tool for epidemiological studies which investigates the relationships between certain risk factors and disease.
Useful tool to improve animal well-being and productivity
Despite of a wealth of suitable studies it is relatively underutilized in animal and veterinary science.
Meta-analysis can provide reliable results about diseases occurrence, pattern and impact in livestock.
It is utmost essential to take benefit of this statistical tool for produce. more reliable estimates of concern effects in animal and veterinary science data.
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...Office of Health Economics
This project seeks to elicit the public’s preferences for different features of a genomic test to sequence advanced solid cancer tumours. Understanding the relative preferences for various attributes of targeted testing are useful for determining the value of sequencing approaches, and informing technology adoption decisions. A discrete choice experiment (DCE) survey was designed to assess the preferences of members of the Australian general public for targeted sequencing in advanced cancer. The survey presented respondents with 12 questions in which they had to choose between two unlabelled tests (Test A and Test B). Tests were specified in terms of five attributes: time to receive the test result; cost of the test; likelihood that the test result will lead to a change in treatment; length of time health care professionals spend describing the test; and type of health care team who explains the test result. Respondents were sampled from an online panel and also completed questions related to demographic and socio-economic factors, experiences of cancer and familial history. We found that cost, timeliness, expertise/location and likeliness of changing treatment regimes were identified as attributes of genomic sequencing that are most valuable to a sample of the public. These results will ultimately be compared with the results of an ongoing DCE being conducted with patients with advanced cancer who are undergoing sequencing.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Grace Hampson (OHE), James Buchanan (Oxford), Melissa Martyn (MGHA), Jayesh Desai (PeterMac), Clara Gaff (MGHA), and iPREDICT MGHA Flagship collaborators
Conference/meeting: EuHEA 2018
Location: Maastricht, the Netherlands
Date: 12/07/2018
Innovative Sample Size Methods For Clinical Trials nQuery
"Innovative Sample Size Methods for Clinical Trials" is hosted to coincide with the Spring 2018 update to nQuery - The leading Sample Size Software.
Hosted by Ronan Fitzpatrick - Head of Statistics and nQuery Lead Researcher at Statsols - you'll learn about the benefits of a range of procedures and how you can implement them into your work:
1) Dose-escalation with the Bayesian Continual Reassessment Method
CRM is a growing alternative to the 3+3 method for Phase I trials finding the Maximum Tolerated Dose (MTD).
See how researchers can overcome 3+3 drawbacks to easily find the required sample size for this beneficial alternative for finding the MTD.
2) Bayesian Assurance with Survival Example
This Bayesian alternative to power has experienced a rapid rise in interest and application from researchers.
See how Assurance is being used by researchers to discover the true “probability of success” of a trial.
3) Mendelian Randomization
Mendelian randomization (MR) is a method that allows testing of a causal effect from observational data in the presence of confounding factors.
However, in order to design efficient Mendelian randomization studies, it is essential to calculate the appropriate sample sizes required. We demonstrate what to do to achieve this.
4) Negative Binomial Distribution
Negative binomial model has been increasingly used to model the count data. One of the challenges of applying negative binomial model in clinical trial design is the sample size estimation.
We demonstrate how best to determine the appropriate sample size in the presence of challenges such as unequal follow-up or dispersion.
Evidence Synthesis for Sparse Evidence Base, Heterogeneous Studies, and Disco...InsideScientific
Standard models in evidence synthesis work well in settings characterized by a large evidence base, the absence of effect modifiers, and connected networks. Handling sparse data, substantial between-study heterogeneity and disconnected studies, however, poses challenges to researchers and requires advanced methodology.
In the absence of head-to-head studies, evidence synthesis is a well-established technique to indirectly compare novel and established interventions in various disease areas. In standard settings, the most established methods for various outcome types work well and result in realistic effect estimates. However, there are a variety of situations when standard methods may no longer be sufficient:
- if there is only a sparse network of evidence
- if there is a large amount of between-study heterogeneity
- if the network is disconnected
Key Topics Include:
- General introduction into the objectives of conducting evidence synthesis
- Description of typical situations of “non-standard” data, including sparse networks of evidence, a large amount of between-study heterogeneity, or disconnected networks
- Advanced methods to address non-standard data, including the use of informative priors, subgroup analyses, meta-regression and multi-level meta regression, and matching-adjusted indirect comparisons (MAICs)
- Case studies illustrating how these advanced methods of evidence synthesis are applied on actual data
OHE’s Professor Nancy Devlin has researched, written and spoken widely on the use of the EQ-5D, and related measures, both in her capacity as the Director of Research at the OHE and as Chair of the Executive Committee of the EuroQol Group.
In May, Nancy was invited to participate in the “Workshop on measuring patient-reported outcomes using the EQ-5D”, which was organised by the Swedish National Board of Health and Welfare in collaboration with the EuroQol Group. The workshop brought together policy makers and researchers in Sweden interested in measuring patients’ health outcomes.
Sweden has included the EQ-5D in some of its quality registries and in population health surveys for many years. The Swedish National Board of Health and Welfare now is exploring whether and how to extend use of patient reported outcomes measures in the health care system, including the EQ-5D, to both monitor the quality of providers and services and to facilitate health technology appraisal.
Nancy’s talk, shown below, introduced the EQ-5D instrument; discussed how data from it can be analysed; identified some of the challenges in analysis; and commented on the future of outcomes measurement.
On 31 October 2019, Adrian Towse and Chris Henshall from the Office of Health Economics (OHE) presented at the G20 meeting on antimicrobial drugs R&D in Paris organised by the Wellcome Trust. The topic of their presentation was HTA and payment mechanisms for new drugs to tackle antimicrobial resistance.
This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian Towse
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
This presentation looks at rates of GDP spend on health care, distinguishing between categories of country (i.e. levels of GDP pre capita). It looks at the relationship between rates of spending and moves to universal health coverage, and explores alternative ways of increasing expenditure and making decisions about which services to provide with the money available.
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
The aim of this educational symposium was to discuss why we should seek value across the health care system and how we can apply existing research methods to measure the value of services. While considerable political attention in developed countries continues to be focused on drug spending, there is also growing awareness of the significant contribution of non-drug components of health care (e.g., hospital services and inefficient care delivery) to overall spending growth and patient affordability. At the same time, there is growing interest in making greater use of value assessment and value-based payment to control spending and better align it with care quality. In order to promote greater value, and to do so in ways that respond to the needs of payers and patients, it is essential to assess value across both drug- and non-drug interventions and health care services. This panel will offer expert viewpoints to identify and discuss gaps in value information, rationale and approaches to track and reduce system-wide low value care, and research methods for how to measure health care services.
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
Graham participated in an organised session on Monday July 15th 2019. In the session he presented his paper with his co-author Ioannis Laliotis from the London School of Economics. The paper revisits the relationship between workforce and maternity outcomes in the English NHS in an attempt to contribute knowledge to an important policy question for which there has been a paucity of research.
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and
which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare
professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
Poster presentation from the EuroQol Plenary Meeting 2019, Brussels, Belgium. By Koonal Shah, Brendan Mulhern, Patricia Cubi-Molla, Bas Janssen, and David Mott.
Koonal presented as part of an organised session on ‘moving beyond conventional economic approaches in palliative and end of life care’. He summarised the empirical evidence on the extent of pubic support for an end of life premium, before discussing some novel approaches that have been used in recent studies. His presentation was discussed by Helen Mason of Glasgow Caledonian University.
Author(s) and affiliation(s): Koonal Shah, Office of Health Economics
Event: iHEA Congress
Date: 17/07/2019
Location: Basel, Switzerland
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and a number of recommendations for adapting these systems to respond to the challenges of AMR.
Author(s) and affiliation(s): Margherita Neri (OHE) Grace Hampson (OHE) Christopher Henshall (OHE visiting fellow, independent consultant) Adrian Towse (OHE)
Event: HTAi annual conference 2019
Date: 18/06/2019
Location: Cologne, Germany
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
This study aims to guide access decisions and drive the discussion on access and price, through recognition of the dynamic nature of value added by pharmaceutical innovation over the long-run. The analysis of the life-cycle value of risperidone estimates the value generated in the UK and Sweden. Results show that health systems were able to appropriate most of the life-cycle value generated, and this is larger than estimated at launch.
Author(s) and affiliation(s): Mikel Berdud(1), Niklas Wallin-Bernhardsson(2), Bernarda Zamora(1), Peter Lindgren(2), and Adrian Towse(1) (1) Office of Health Economics (2) The Swedish Institute for. Health Economics
Event: XXXIX JORNADAS DE ECONOMÍA DE LA SALUD
Date: 12/06/2019
Location: Albacete, Spain
Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina Rodes Sanchez described the key features of the schemes and discussed its strengths and weaknesses based on international pay-for-performance literature.
Author(s) and affiliation(s): Yan Feng, Queen Mary University of London; Søren Rud Kristensen, Imperial College London; Paula Lorgelly, King’s College London; Rachel Meacock, University of Manchester; Marina Rodes Sanchez, Office of Health Economics; Luigi Siciliani, University of York; Matt Sutton, University of Manchester
Event: XXXIX Spanish Health Economics Association Conference
Date: 12/06/2019
Location: Albacete, Spain
In this session, Meng Li sets out estimates of real option value for drugs arguing that option value matters and can be calculated. Adrian Towse sets out likely payer concerns about incorporating real option value into decision making. Meng Li responds to these concerns. Jens Grueger sets out how industry considers investment opportunities, arguing that if patients (and society) have preferences these need to be reflected in P&R decisions.
Author(s) and affiliation(s): Meng Li, Postdoctoral Research Fellow, Leonard D Schaeffer Center, University of Southern California, Los Angeles, CA, USA. Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Jens Grueger, formerly Head of Global Access, Senior Vice President at F. Hoffmann-La Roche
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
In this ISPOR session Chuck Phelps and Adrian Towse debated the case for and against using MCDA to support HTA decision making, as compared to weighting or augmenting a QALY based ICER approach. Chuck Phelps argued for use of MCDA, Adrian Towse for weighting the QALY. Nancy Devlin set the scene and moderated.
Author(s) and affiliation(s): Nancy Devlin, Director, Centre for Health Policy, University of Melbourne, Australia Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Chuck Phelps, University of Rochester, Rochester, NY USA
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
This presentation, created by Syed Faiz ul Hassan, explores the profound influence of media on public perception and behavior. It delves into the evolution of media from oral traditions to modern digital and social media platforms. Key topics include the role of media in information propagation, socialization, crisis awareness, globalization, and education. The presentation also examines media influence through agenda setting, propaganda, and manipulative techniques used by advertisers and marketers. Furthermore, it highlights the impact of surveillance enabled by media technologies on personal behavior and preferences. Through this comprehensive overview, the presentation aims to shed light on how media shapes collective consciousness and public opinion.
0x01 - Newton's Third Law: Static vs. Dynamic AbusersOWASP Beja
f you offer a service on the web, odds are that someone will abuse it. Be it an API, a SaaS, a PaaS, or even a static website, someone somewhere will try to figure out a way to use it to their own needs. In this talk we'll compare measures that are effective against static attackers and how to battle a dynamic attacker who adapts to your counter-measures.
About the Speaker
===============
Diogo Sousa, Engineering Manager @ Canonical
An opinionated individual with an interest in cryptography and its intersection with secure software development.
Acorn Recovery: Restore IT infra within minutesIP ServerOne
Introducing Acorn Recovery as a Service, a simple, fast, and secure managed disaster recovery (DRaaS) by IP ServerOne. A DR solution that helps restore your IT infra within minutes.
Have you ever wondered how search works while visiting an e-commerce site, internal website, or searching through other types of online resources? Look no further than this informative session on the ways that taxonomies help end-users navigate the internet! Hear from taxonomists and other information professionals who have first-hand experience creating and working with taxonomies that aid in navigation, search, and discovery across a range of disciplines.
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...Orkestra
UIIN Conference, Madrid, 27-29 May 2024
James Wilson, Orkestra and Deusto Business School
Emily Wise, Lund University
Madeline Smith, The Glasgow School of Art
This presentation by Morris Kleiner (University of Minnesota), was made during the discussion “Competition and Regulation in Professions and Occupations” held at the Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found out at oe.cd/crps.
This presentation was uploaded with the author’s consent.
Getting started with Amazon Bedrock Studio and Control Tower
Value of transferability and efficiency in HTA
1. Value of Transferability and
Efficiency in HTA
Bernarda Zamora, Grace Marsden, Adrian Towse
Email: bzamora@ohe.org
1. BACKGROUND
• Existing literature on transferability advises that multinational
trials should report country-specific cost-effectiveness results,
yet typically these country specific results are only used to
assess the between-location variability.
• We use value of information (VOI) analysis (assuming a normal
distribution) to show that country specific results can be used to
calculate the value of transferability (transfer from the wide trial
to the country of interest) in terms of the Expected Value of
Sample Information (EVSI).
• Our contribution lies in the definition of the posterior distribution
of the country results given the wide trial results.
Acknowledgements
This presentation has benefitted from comments at the OHE Research
team meeting. Special thanks to Ed Wilson.
References
Briggs, Andrew, Mark Sculpher, and Karl Claxton, 2006. Decision modelling for health economic evaluation, Oxford University Press.
Burton, P. R., 1994. Helping doctors to draw appropriate inferences from the analysis of medical studies, Stat Med 13(17), pp. 1699-1713.
Claxton, K. and K. M. Thompson, 2001. A dynamic programming approach to the efficient design of clinical trials, J Health Econ 20(5), pp. 797-822.
Cook, J. R., M. Drummond, H. Glick, and J. F. Heyse, 2003. Assessing the appropriateness of combining economic data from multinational clinical trials,
Stat Med 22(12), pp. 1955-1976.
Gelman, Andrew, John B Carlin, Hal S Stern, and Donald B Rubin, 2014. Bayesian data analysis, Taylor & Francis.
Manca, A., P. C. Lambert, M. Sculpher, and N. Rice, 2007. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical
modeling, Med Decis Making 27(4), pp. 471-490
Spiegelhalter, David J, Keith R Abrams, and Jonathan P Myles, 2004. Bayesian approaches to clinical trials and health-care evaluation, John Wiley & Sons.
Wilson, E. C., 2015. A practical guide to value of information analysis, Pharmacoeconomics 33(2), pp. 105-121.
2. AIMS
• To calculate the value of transferability (transfer from the wide
trial to the country of interest) in terms of the Expected Value of
Sample Information.
• To test this method on the results of the Scandinavian
Simvastatin Survival Study published by Cook et al. (2003).
3. METHODS
1. Posterior distribution of country n INMB: Bayesian Conjugate
Normal Analysis & Sequential use of Bayes theorem:
If the vector 𝑦 𝑛, 𝑦 𝑚 denotes the INMB of the individual country n,
and the wide trial m
𝑝 𝜃 𝑦 𝑛, 𝑦 𝑚 = 𝑁 𝜃𝑛
𝑦 𝑚
𝜎 𝑚
2
1 − 𝜌2 +
𝑦 𝑛
𝜎 𝑛
2
1
𝜎 𝑚
2
1 − 𝜌2 +
1
𝜎 𝑛
2
,
1
1
𝜎 𝑚
2
1 − 𝜌2 +
1
𝜎 𝑛
2
2. Value of Transferability in terms of Value of Information:
Prior EVPI: associated with the normal marginal distribution of
each country result.
Posterior EVPI: associated with the distribution obtained above
Value of Transferability = EVSI = Prior EVPI – Posterior EVPI
4.RESULTS
Figure 1: Distribution of Net Benefit
5. DISCUSSION
• It has been argued that in absence of significant between-
country differences in the parameters of interest, the wide trial
pooled results should be adopted by each country as the
“generalisable/transferable” results.
• Building on Bayesian statistical properties and VOI, it is possible
to further assess the appropriateness of the transferability of
wide trial results by valuing the benefits from reducing
uncertainty, or the cost from increasing uncertainty.
• Our method relies on conjugate normality. Although this is a
restrictive assumption, it allows us to fully define the posterior
distribution from published results on just CE means and
variances of countries and wide trial.
• Even though Cook et al.’s (2003) results imply that it would be
appropriate for each country to reimburse Simvastatin according
to the wide trial CE pooled results, we show that the
transferability of the wide trial decision is not appropriate for
Finland and Iceland.
• We measure the value of transferability in terms of monetary
benefits or costs.
.6.7.8.9
1
-1 -.5 0 .5 1
rho
Denmark
.6.7.8.9
1
-1 -.5 0 .5 1
rho
Sweden
.75
.8
.85
.9
.95
1
-1 -.5 0 .5 1
rho
Norway
0
.1.2.3.4
-1 -.5 0 .5 1
rho
Finland
0
.2.4.6
-1 -.5 0 .5 1
rho
Iceland
Implicit rho from bivariate normality
Posterior decision of
reimbursement:
Yes for all countries,
given the trial-wide
results
Denmark Finland Iceland Norway Sweden
Prior EVPI $43,555,214 $31,219,711 $4,900,946 $16,535,958 $49,568,440
ΔBj¦ ΔB.
Conditional mean INMB
$525 $525 $525 $525 $525
SE(ΔBj/ ΔB.) :
Conditional standard
error of mean INMB
$363.97 $372.68 $689.29 $0 $330.00
Posterior mean $547.40 $549.20 $478.96 $525 $526.14
Posterior standard error $357.88 $358.37 $675.57 $0 $316.22
Posterior absolute
normalised mean
1.53 1.53 0.71 - 1.66
Posterior probability of
wrong decision
6.31% 93.73% 23.92% 0% 4.81%
L(ΔB0,SE(ΔB)0) :unit
normal loss
0.027 1.444 0.141 0.000 0.020
Posterior EVPI $1,320,739 $86,112,293 $438,135 $0 $1,409,515
Value of Transferability:
Prior EVPI-Posterior
EVPI
$42,234,475 -$54,892,581 NA $16,535,958 $48,158,925
-10,000 -5,000 0 5,000 10,000
Finland Iceland
WideTrial Sweden
Denmark Norway
Figure 2: Correlation with Multinational results
6. CONCLUSION
Table 1: Posterior distribution of INMB and Value of Transferability